Survival

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk

Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk

By

Whole genome sequencing of more than 3000 survivors of childhood cancers demonstrates the value of genetic testing for potential second cancers in this population.

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

By

Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.

Annual Report Shows Decline in Cancer Death Rates, 1975-2014

Annual Report Shows Decline in Cancer Death Rates, 1975-2014

By

The joint report states that overall cancer rates have decreased for men, women, and children in all major race and ethnic groups. However, progress has been limited for some cancers.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST

SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST

By

A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

By

Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.

SCLC: No Benefit from Pravastatin When Added to First-line Chemo

SCLC: No Benefit from Pravastatin When Added to First-line Chemo

By

The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

By

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

HNSCC Survival Worse for Patients in Lower Socioeconomic Population

HNSCC Survival Worse for Patients in Lower Socioeconomic Population

By

Investigators determined the impact of socioeconomic status on disease status at presentation and survival among patients with head and neck squamous cell carcinoma.

Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer

Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer

By

Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

By

There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.

Early Endometrial Cancer Surgery May Reduce Survival

Early Endometrial Cancer Surgery May Reduce Survival

By

The timing of surgery taking place following an endometrial cancer diagnosis may adversely impact survival.

Selumetinib + MK-2206 Fails to Improve Survival vs mFOLFOX in Pancreatic Cancer

Selumetinib + MK-2206 Fails to Improve Survival vs mFOLFOX in Pancreatic Cancer

By

Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.

Social Isolation Can Adversely Affect Breast Cancer Survival

Social Isolation Can Adversely Affect Breast Cancer Survival

Weak social ties are associated with poorer survival and a higher risk of breast cancer recurrence, researchers say.

Palliative Care Provides Benefits, But Does Not Extend Life for Patients With Cancer

Palliative Care Provides Benefits, But Does Not Extend Life for Patients With Cancer

By

A new meta-analysis examines the impact of palliative care services on patients' and caregivers' quality of life and outcomes.

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

By

Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.

SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC

By

Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.

Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC

By

The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Outcomes in Patients With Brain Metastasis from Esophageal Carcinoma

Outcomes in Patients With Brain Metastasis from Esophageal Carcinoma

[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.

HIV Infection Worsens Survival of Patients With Cervical Cancer

HIV Infection Worsens Survival of Patients With Cervical Cancer

By

HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

By

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

By

Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.

Metformin Use May Improve Survival in Patients With CRC, Diabetes

By

Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.

Adding Daratumumab to Lenalidomide/Dexamethasone Improves Survival in Multiple Myeloma

Adding Daratumumab to Lenalidomide/Dexamethasone Improves Survival in Multiple Myeloma

By

Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

By

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs